Recordati SpA REC

MIL: REC | ISIN: IT0003828271   5/06/2025
52,95 EUR (+0,67%)
(+0,67%)   5/06/2025
Grafiek Recordati SpA Grafiek Recordati SpA

Recordati SpA in het nieuws

15 mei 2025 · Recordati: To Be Highlighted At American Association Of Clinical Endocrinology (Aace) Annual Meeting--The Expanded Indication For Isturisa® (Osilodrostat) For The Treatment Of Endogenous Hypercortisolemia In Adult Patients With Cushing's Syndrome For Whom Surgery Is Not An Option Or Has Not Been Curative · Persbericht

8 mei 2025 · Recordati: Strong Momentum Of The Group Continues Into The First Quarter Of 2025 Revenue +11.9%, Ebitda(1) +10.7%, Adjusted Net Income(2) +7.2% · Persbericht

28 april 2025 · Recordati: 2025-2027 Three-Year Plan Approved Fy 2027 Targets Of Revenue Between € 3,000 And € 3,200 Million; Ebitda(1) Between € 1,140 And € 1,225 Million; Adjusted Net Income(2) Between € 770 And € 820 Million · Persbericht

16 april 2025 · Recordati: Fda Grants Isturisa® (Osilodrostat) Expanded Indication For The Treatment Of Endogenous Hypercortisolemia In Patients With Cushing’s Syndrome · Persbericht

13 februari 2025 · Recordati: Preliminary Results For Full Year 2024 Revenue +12.4%, Ebitda(1) +12.5%, Adjusted Net Income(2) +8.4% Peak Year Sales Targets Raised For Key Rare Diseases Products · Persbericht

8 november 2024 · Recordati: Continued Double-Digit Growth In The First Nine Months Of 2024 - Revenue +12.0%, Ebitda(1) +11.8%, Adjusted Net Income(2) +9.5% · Persbericht

4 oktober 2024 · Recordati Announces Agreement To Acquire The Global Rights To Enjaymo®, Strengthening Its Rare Diseases Franchise · Persbericht

23 maart 2021 · Recordati: Positive Results From The Phase Iii Linc 4 Study Presented At The Endocrine Society’s Annual Meeting Reinforce The Efficacy And Safety Of Isturisa® (Osilodrostat) In Cushing’s Disease · Persbericht

22 februari 2021 · Recordati: Preliminary 2020 Results Confirm Continued Growth Of Operating Income And Net Income. Ebitda +4.7% And Adjusted Net Income +7.3%. · Persbericht

29 januari 2021 · Recordati: License Obtained For The Commercialization Of Eligard In Europe And Other Countries · Persbericht

Profiel Recordati SpA

CEO: Andrea Recordati

Mijn selecties